RNS Number : 9571V MaxCyte, Inc. 20 April 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") MaxCyte Reports Final Results for the Year Ended 31 December 2020 Gaithersburg , Maryland - 20 April 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), a leading provider of cell-engineering
RNS Number : 5163V MaxCyte, Inc. 15 April 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Notice of Full Year Results Gaithersburg, Maryland - 15 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), a leading provider of cell-engineering platform technologies for
RNS Number : 2232U MaxCyte, Inc. 01 April 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block
RNS Number : 0007S MaxCyte, Inc. 11 March 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
Released : March 03, 2021 07:00 RNS Number : 9363Q MaxCyte, Inc. 03 March 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Gaithersburg, Maryland - 3 March 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces
Released : February 23, 2021 07:00 RNS Number : 9618P MaxCyte, Inc. 22 February 2021 FOR IMMEDIATE RELEASE MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences GAITHERSBURG, MD , February 23, 2021 - MaxCyte, Inc., a global cell-based
Released : February 19, 2021 07:00 RNS Number : 6562P MaxCyte, Inc. 19 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings and Issue of Equity Total Voting Rights Gaithersburg, Maryland - 19 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global
Released : February 17, 2021 17:44 RNS Number : 4895P MaxCyte, Inc. 17 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, Maryland - 17 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global clinical-stage cell-based therapies and life sciences
Released : February 15, 2021 16:32 RNS Number : 1618P MaxCyte, Inc. 15 February 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : February 12, 2021 13:59 RNS Number : 9907O MaxCyte, Inc. 12 February 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
